花旗研究报告指，康哲药业(00867.HK) 2025年收入按年增长9.9%至82.12亿元人民币(下同)，符合该行及市场预期。净利润按年下跌8.1%至14.89亿元，较该行及市场预期低12%及11%，主要由于与西藏药业相关的税务优惠被取消而产生一次性税务支出2.79亿元。撇除此因素，净利润应为17.75亿元，按年增长3.6%。根据管理层最新对创新药快速增长的指引，该行上调2026及2027年收入...
Source Link花旗研究报告指，康哲药业(00867.HK) 2025年收入按年增长9.9%至82.12亿元人民币(下同)，符合该行及市场预期。净利润按年下跌8.1%至14.89亿元，较该行及市场预期低12%及11%，主要由于与西藏药业相关的税务优惠被取消而产生一次性税务支出2.79亿元。撇除此因素，净利润应为17.75亿元，按年增长3.6%。根据管理层最新对创新药快速增长的指引，该行上调2026及2027年收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.